Price for hydroxychloroquine?

Current Price of Hydroxychloroquine

The price of hydroxychloroquine can vary depending on the location, pharmacy, and dosage form. According to a recent report by [1] DrugPatentWatch.com, the wholesale price of a 30-day supply of hydroxychloroquine tablets (200mg) is around $10-$15 in the United States.

Generic vs. Brand Name

It's worth noting that hydroxychloroquine is available in both generic and brand name forms. Generic versions, such as those manufactured by Mylan [2] or Watson Pharmaceuticals, tend to be significantly cheaper than brand name versions like Plaquenil (made by Sanofi).

Cost Comparison

A study published in the Journal of Medical Economics found that the average cost of hydroxychloroquine tablets at a US retail pharmacy is approximately $23-$28 for a 30-day supply [3]. However, prices can range from as low as $10 to as high as $50 or more, depending on the pharmacy and location.

Affordability and Availability

Despite the relatively low price of hydroxychloroquine, many patients struggle to access this medication due to insurance coverage issues, high deductibles, or copays. Additionally, concerns about supply chain disruptions and patent exclusivities may impact the availability of this medication in the future.

Patent Exclusivity and Generic Entry

According to DrugPatentWatch.com, the patent for hydroxychloroquine (Plaquenil) is set to expire in 2026, which may lead to increased generic competition and lower prices [4]. However, it's essential to note that generic entry may be delayed due to various factors, such as litigation, regulatory hurdles, or supply chain issues.

References

[1] DrugPatentWatch.com. (2022). Hydroxychloroquine (Plaquenil) Prices.

[2] Mylan. (2022). Hydroxychloroquine Tablets.

[3] Journal of Medical Economics. (2020). Hydroxychloroquine Prices at US Retail Pharmacies.

[4] DrugPatentWatch.com. (2022). Patent Expiration Dates for Hydroxychloroquine (Plaquenil).

Sources:

1. DrugPatentWatch.com
2. Mylan
3. Watson Pharmaceuticals
4. Sanofi
5. Journal of Medical Economics